La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
874 Panoramica delle azioni
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, insieme alle sue consociate, ricerca, sviluppa, produce e vende farmaci cinesi brevettati e occidentali, materie prime chimiche, farmaci naturali e biologici e intermedi di materie prime chimiche nella Repubblica Popolare Cinese e a livello internazionale.
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 4/6 |
Premi
Analisi del rischio
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Concorrenti
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | HK$19.24 |
| Massimo di 52 settimane | HK$24.20 |
| Minimo di 52 settimane | HK$18.48 |
| Beta | 0.56 |
| 1Variazione di 1 mese | -4.04% |
| Variazione a 3 mesi | -14.11% |
| Variazione di 1 anno | -8.82% |
| 3Variazione a 3 anni | -2.93% |
| Variazione a 5 anni | -34.45% |
| Variazione dall'IPO | 1,335.82% |
Notizie e aggiornamenti recenti
A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03Recent updates
A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Rendimenti per gli azionisti
| 874 | HK Healthcare | HK Mercato | |
|---|---|---|---|
| 7D | -2.8% | -4.3% | 0.3% |
| 1Y | -8.8% | -29.9% | 4.0% |
Ritorno vs Industria: 874 ha superato il Hong Kong Healthcare che ha restituito -30.6 % nell'ultimo anno.
Rendimento vs Mercato: 874 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 6.2 % nell'ultimo anno.
Volatilità dei prezzi
| 874 volatility | |
|---|---|
| 874 Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.1% |
| 10% least volatile stocks in HK Market | 3.3% |
Prezzo delle azioni stabile: 874 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di 874 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1997 | 28,048 | Hong Li | www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, insieme alle sue consociate, ricerca, sviluppa, produce e vende farmaci cinesi brevettati e occidentali, materie prime chimiche, farmaci naturali e biologici e intermedi di materie prime chimiche nella Repubblica Popolare Cinese e a livello internazionale. L'azienda opera attraverso i segmenti Great Southern TCM, Great Commerce, Great Health e Other. L'azienda si occupa anche di vendita all'ingrosso, al dettaglio, vendita, importazione ed esportazione di medicinali occidentali e cinesi, strumenti medici, prodotti farmaceutici, attrezzature mediche e prodotti sanitari; ricerca e sviluppo, produzione e vendita di bevande, alimenti, prodotti sanitari e altri prodotti; produzione e vendita di alimenti preconfezionati, prodotti lattiero-caseari, ecc.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Riepilogo dei fondamenti
| 874 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | HK$48.97b |
| Guadagni(TTM) | HK$4.49b |
| Ricavi(TTM) | HK$84.07b |
7.0x
Rapporto P/E0.4x
Rapporto P/S874 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneGuadagni e ricavi
| 874 Conto economico (TTM) | |
|---|---|
| Ricavi | CN¥76.83b |
| Costo del fatturato | CN¥62.65b |
| Profitto lordo | CN¥14.19b |
| Altre spese | CN¥10.08b |
| Guadagni | CN¥4.11b |
Ultimi guadagni dichiarati
Mar 31, 2024
Prossima data di guadagno
Aug 30, 2024
| Utile per azione (EPS) | 2.53 |
| Margine lordo | 18.46% |
| Margine di profitto netto | 5.34% |
| Rapporto debito/patrimonio netto | 34.2% |
Come si è comportato 874 nel lungo periodo?
Vedi performance storica e confronto